10 web-developer-"https:"-"https:"-"https:" uni jobs at Center for Biologics Evaluation and Research (CBER)

FDA Research Opportunity - Influenza Vaccine Assay Development

Center for Biologics Evaluation and Research (CBER) | Silver Spring, Maryland | United States | about 2 hours ago

related products including blood, vaccines, allergenics, tissues, and cellular and gene therapies. Research Project: The development of vaccines against viral diseases that are major public health concerns

FDA Research Opportunity - Developing Methods for Efficient Gene Editing in Hematopoietic Stem Cells (HSCs)

Center for Biologics Evaluation and Research (CBER) | Silver Spring, Maryland | United States | about 2 hours ago

the regulation of biological and related products including blood, vaccines, allergenics, tissues, and cellular and gene therapies. Research Project: This research project focuses on advancing the development and

FDA Research Opportunity in Developing Methods for Efficient Gene Editing in Hematopoietic Stem Cells (HSCs)

Center for Biologics Evaluation and Research (CBER) | Silver Spring, Maryland | United States | 13 days ago

the regulation of biological and related products including blood, vaccines, allergenics, tissues, and cellular and gene therapies. Research Project: This research project focuses on advancing the development and

FDA Non-clinical Identification and Mitigation of Safety Risks During the Development and Licensure of Protein-therapeutics

Center for Biologics Evaluation and Research (CBER) | Silver Spring, Maryland | United States | 19 days ago

human pathogens are the most extensively studied CRISPR-Cas gene editors.  An important hurdle when developing and licensing a protein for clinical applications is the potential for immune responses

FDA Research Opportunity - Dengue Neutralization Assay

Center for Biologics Evaluation and Research (CBER) | Silver Spring, Maryland | United States | about 2 hours ago

of this fellowship is to develop and apply methods to evaluate viral vaccines, including their strength, durability of immune responses, performance across different platforms, and safety profiles. The fellowship

FDA Research Opportunity - Immune Responses to Influenza Vaccines

Center for Biologics Evaluation and Research (CBER) | Silver Spring, Maryland | United States | 12 days ago

or influenza infections and vaccination in humans as well as novel vaccine adjuvants and mucosal vaccines. The participant will be trained in advanced techniques developed in the lab including virus

FDA Research Opportunity - Detection of Emerging Pathogens that Threaten Blood Safety

Center for Biologics Evaluation and Research (CBER) | Southern Md Facility, Maryland | United States | 12 days ago

models of transfusion transmission. These models will be used to: Develop methods and tools to evaluate the performance of assays/tests for virus detection and understand how virus genetic variation

FDA Tick-Borne Pathogen Research Program

Center for Biologics Evaluation and Research (CBER) | Southern Md Facility, Maryland | United States | about 2 hours ago

for causing a disease called anaplasmosis in humans. This research involves establishment of an animal model for A. phagocytophilum, determining the minimum infectious dose of infection and developing novel

FDA Evaluation of Platelets: Antimicrobial Treatments and Evaluation of the Treated Products for Functions

Center for Biologics Evaluation and Research (CBER) | Southern Md Facility, Maryland | United States | 13 days ago

on the functions of the blood components such as platelets etc. Development of functional quality biomarkers for blood components such as platelets Learning Objectives: By the end of this training opportunity, you

FDA Evaluation and Characterization of Neutralizing Antibodies Against Viruses Relevant to Blood-Derived Products

Center for Biologics Evaluation and Research (CBER) | Silver Spring, Maryland | United States | 13 days ago

of hepatitis viruses and developing assay protocols to monitor virus-neutralizing activities of immunoglobulin intravenous (IGIV) products. The following articles in the literature provide examples of the range